Pharmaceuticals & Healthcare Analysis

Pages

Industry Trend Analysis - Political Risks To Dampen Turkey's Attractiveness For Drug Production - NOV 2017

Investment in domestic drug production will continue to accelerate across the CEE region, driven by government policies. However, we note that the considerable political instability in Turkey will prevent the market from realising its ambitious goals. On the other hand, investment into Russia's pharmaceutical industry by multinational pharmaceutical firms will continue.

READ FULL ARTICLE

Industry Trend Analysis - Novartis Will Take Advantage Of Ibrance's Slow Movement In EU - OCT 2017

The approval of Kisqali in the EU will aid Novartis' ambitious growth plans for this drug. It will lag behind the market leader, Pfizer's Ibrance, which has capitalised on first-to-market status. Novartis has an opening to gain market share in Europe, which will be supported by its flexible pricing strategies as Pfizer struggles to gain traction with Ibrance in this region.

READ FULL ARTICLE

Pages